Verve Therapeutics, Inc. (VERV)
Jul 25, 2025 - VERV was delisted (reason: acquired by LLY)
11.13
0.00 (0.00%)
Inactive · Last trade price on Jul 24, 2025
Verve Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 96.55 | 172.56 | 206.18 | 115.41 | 64.33 | 8.99 |
Short-Term Investments | 400.52 | 351.72 | 417.77 | 439.4 | 296.11 | 63.12 |
Cash & Short-Term Investments | 497.08 | 524.28 | 623.95 | 554.81 | 360.44 | 72.11 |
Cash Growth | -18.02% | -15.97% | 12.46% | 53.92% | 399.84% | 283.94% |
Receivables | 1.4 | 3.26 | 5.9 | 1.01 | - | - |
Prepaid Expenses | 13.17 | 15.22 | 8.1 | 7.34 | 6.69 | 1.85 |
Total Current Assets | 511.65 | 542.75 | 637.95 | 563.16 | 367.13 | 73.97 |
Property, Plant & Equipment | 94.67 | 96.73 | 107.8 | 110.66 | 9.06 | 3.98 |
Other Long-Term Assets | 7.84 | 7.92 | 6.94 | 5.41 | 7.93 | 0.46 |
Total Assets | 614.16 | 647.39 | 752.69 | 679.22 | 384.12 | 78.41 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 5.35 | 4.52 | 6.64 | 2.42 | 7.08 | 0.04 |
Accrued Expenses | 17.05 | 24.34 | 19.68 | 20.46 | 12.99 | 7.19 |
Current Portion of Leases | 10.52 | 10.44 | 10.19 | 11.9 | 1.96 | - |
Current Unearned Revenue | 19.06 | 3.61 | - | - | - | - |
Other Current Liabilities | - | - | 0.5 | 0.31 | - | 0.09 |
Total Current Liabilities | 51.98 | 42.91 | 37.01 | 35.1 | 22.02 | 7.32 |
Long-Term Leases | 58.12 | 59.54 | 64.72 | 70.01 | - | - |
Long-Term Unearned Revenue | 29.52 | 50.27 | 48.56 | 20.01 | - | - |
Other Long-Term Liabilities | 1.03 | 1.28 | 2.91 | 3.17 | 4.75 | 9.85 |
Total Liabilities | 140.65 | 153.99 | 153.19 | 128.29 | 26.77 | 17.16 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0.09 | 0.09 | 0.08 | 0.06 | 0.05 | 0 |
Additional Paid-In Capital | 1,247 | 1,236 | 1,143 | 895.8 | 544.38 | 2.62 |
Retained Earnings | -774.05 | -743.01 | -544.31 | -344.24 | -186.85 | -66.54 |
Comprehensive Income & Other | 0.39 | 0.43 | 0.27 | -0.69 | -0.23 | 0.01 |
Total Common Equity | 473.51 | 493.4 | 599.5 | 550.93 | 357.35 | -63.91 |
Shareholders' Equity | 473.51 | 493.4 | 599.5 | 550.93 | 357.35 | 61.25 |
Total Liabilities & Equity | 614.16 | 647.39 | 752.69 | 679.22 | 384.12 | 78.41 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 68.64 | 69.98 | 74.91 | 81.92 | 1.96 | - |
Net Cash (Debt) | 428.44 | 454.3 | 549.04 | 472.89 | 358.49 | 72.11 |
Net Cash Growth | -19.57% | -17.26% | 16.10% | 31.91% | 397.13% | 682.89% |
Net Cash Per Share | 4.97 | 5.36 | 8.56 | 8.75 | 13.34 | 32.05 |
Filing Date Shares Outstanding | 89.14 | 88.8 | 83.62 | 61.83 | 48.58 | 2.18 |
Total Common Shares Outstanding | 88.8 | 88.76 | 81.97 | 61.73 | 48.51 | 2.18 |
Working Capital | 459.67 | 499.84 | 600.94 | 528.06 | 345.1 | 66.65 |
Book Value Per Share | 5.33 | 5.56 | 7.31 | 8.92 | 7.37 | -29.28 |
Tangible Book Value | 473.51 | 493.4 | 599.5 | 550.93 | 357.35 | -63.91 |
Tangible Book Value Per Share | 5.33 | 5.56 | 7.31 | 8.92 | 7.37 | -29.28 |
Machinery | 36.51 | 34.98 | 32.17 | 23.5 | 9.29 | 4.52 |
Leasehold Improvements | 0.78 | 0.78 | 0.73 | 0.27 | 0.27 | 0.26 |